이 유전자는 효소의 시토크롬 P450 슈퍼패밀리의 구성원을 암호로 한다.시토크롬 P450 단백질은 약물 대사 및 콜레스테롤, 스테로이드 및 기타 지질의 합성에 관련된 많은 반응을 촉진하는 단옥시겐이다.이 단백질은 소포체 망막까지 국소화된다.내생성 기질이 결정되지는 않았지만 담배 특유의 주요 니트로사민인 4-(메틸니트로사미노)-1-(3-피리딜)-1-부타논을 대사하는 것으로 알려져 있다.이 유전자는 19q 염색체의 CYP2A, CYP2B, CYP2F 하위가족에서 나온 사이토크롬 P450 유전자의 큰 군집의 일부다.[7]
Fernandez-Salguero P, Gonzalez FJ (1995). "The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis". Pharmacogenetics. 5 (Special Issue): S123–8. doi:10.1097/00008571-199512001-00013. PMID7581481.
Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica. 28 (12): 1129–65. doi:10.1080/004982598238868. PMID9890157.
Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW (1996). "Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19". J. Mol. Evol. 41 (6): 894–900. doi:10.1007/bf00173169. PMID8587134. S2CID12153961.
Koskela S, Hakkola J, Hukkanen J, et al. (1999). "Expression of CYP2A genes in human liver and extrahepatic tissues". Biochem. Pharmacol. 57 (12): 1407–13. doi:10.1016/S0006-2952(99)00015-5. PMID10353262.
Su T, Bao Z, Zhang QY, et al. (2000). "Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone". Cancer Res. 60 (18): 5074–9. PMID11016631.
Zhang X, Su T, Zhang QY, et al. (2002). "Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant". J. Pharmacol. Exp. Ther. 302 (2): 416–23. doi:10.1124/jpet.302.2.416. PMID12130698.
Wang H, Tan W, Hao B, et al. (2004). "Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK". Cancer Res. 63 (22): 8057–61. PMID14633739.
Cauffiez C, Lo-Guidice JM, Quaranta S, et al. (2004). "Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility". Biochem. Biophys. Res. Commun. 317 (2): 662–9. doi:10.1016/j.bbrc.2004.03.092. PMID15063809.
Cheng XY, Chen GL, Zhang WX, et al. (2004). "Arg257Cys polymorphism of CYP2A13 in a Chinese population". Clin. Chim. Acta. 343 (1–2): 213–6. doi:10.1016/j.cccn.2004.01.017. PMID15115698.
He XY, Shen J, Ding X, et al. (2005). "Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen". Drug Metab. Dispos. 32 (12): 1516–21. doi:10.1124/dmd.104.001370. PMID15333516. S2CID26225467.
Fujieda M, Yamazaki H, Kiyotani K, et al. (2005). "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese". Drug Metab. Pharmacokinet. 18 (1): 86–90. doi:10.2133/dmpk.18.86. PMID15618722.
